• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 4, 2014

View Archived Issues

Amgen takes 'BiTE' out of cancer immunotherapy market with speedy Blincyto approval

The FDA Wednesday afternoon granted accelerated approval with breakneck speed – more than five months ahead of its May 19, 2015, PDUFA date – to Amgen Inc.'s blinatumomab to treat patients with relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, or B-cell ALL, a rare form of ALL. Read More

Naurex raises $80M to knock out depression

Naurex Inc. raised an $80 million series C to carry its fast-acting experimental depression therapy, the NMDA receptor modulator GLYX-13, into its first phase III study in mid-2015. Read More

Buy-side, sell-side perspectives on navigating early stage innovation game

LILLE, France – Big pharma's focus on early stage innovation is obviously good news for early stage innovators, particularly those who have managed to bring their projects through the valley of death, to the point where they have established technical proof of concept. Read More

On the cusPIDD of a win? Adma's phase III results have teeth, final next year

Taking what CEO Adam Grossman called "a different spin on intravenous immunoglobulin [IVIG]" while "trying to provide a product that's very targeted, niche-focused, and is going to provide an advantage to a subset" of the patient population, Adma Biologics Inc. reported positive top-line phase III results in primary immune deficiency diseases (PIDD) with lead compound RI-002. Read More

$308M Sanofi, Evotec pact aims to ramp up innovation efficiency

LONDON – Evotec AG is lining up a three-armed deal with Sanofi SA, which will see it taking on responsibility for five preclinical oncology programs, assuming operational control of a 200-strong drug discovery facility and acting as chief scout for academic research projects on behalf of the French pharma company. Read More

Sinopharm subsidiary inks deal with Aeterna for endometrial cancer drug

HONG KONG – Aeterna Zentaris Inc. and Sinopharm A-think Pharmaceuticals Co. Ltd. signed an exclusive license and technology transfer agreement allowing Sinopharm A-think to develop, manufacture and commercialize Aeterna Zentaris' zoptarelin doxorubicin (AEZS-1-8) in China, Hong Kong and Macau. The drug is being developed to treat endometrial cancer. Read More

Immune cell discovery may lead to new MS treatments

HONG KONG – The breakthrough discovery of a new type of immune cells may play a key role in development of a treatment for multiple sclerosis (MS), a multi-disciplinary National University of Singapore (NUS) research team reported in Cell Research. Read More

Stock movers

Read More

Other news to note

Puma Biotechnology Inc., of Los Angeles, said it will need to submit data from preclinical carcinogenicity studies with its new drug application (NDA) filing for PB272 (neratinib) in the extended adjuvant treatment of HER2-positive early stage breast cancer. Consequently, the company plans to delay the proposed timeline for filing the NDA from the first half of 2015 until the first quarter of 2016. Read More

In the clinic

Lpath Inc., of San Diego, completed enrollment of its clinical trial evaluating Isonep in patients with wet age-related macular degeneration. The multicenter phase II trial enrolled patients who have not responded well to existing anti-vascular endothelial growth factor therapies including, Lucentis (ranibizumab, Genentech Inc./Roche AG), Avastin (bevacizumab, Genentech Inc./Roche AG) and Eylea (aflibercept, Regeneron Pharmaceuticals Inc./Bayer AG). Read More

Financings

Ocata Therapeutics Inc., of Marlborough, Mass., said it plans to offer 10 million shares of its common stock in an underwritten public offering under an existing shelf registration statement. As part of this offering, the company intends to grant the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock. The offering has not yet been priced. Read More

Pharma: Other news to note

Meda Pharmaceuticals Inc., of Goteborg, Sweden, and Cipla Ltd., of Mumbai, India, said they sued Apotex Inc., of Toronto, along with U.S. arm Apotex Corp., in Federal District Court in Delaware to enforce the Orange Book-listed patents covering Dymista (azelastine HCl/fluticasone propionate) nasal spray, in response to Apotex's submission to the FDA of an abbreviated new drug application and accompanying paragraph IV certification, seeking approval to market a generic version of Meda's Dymista prior to expiration of the Dymista patents. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe